Skip to main content
Premium Trial:

Request an Annual Quote

CAS Inks Agreements with NIH to Provide Access to Chemistry Resource

Premium

The Chemical Abstracts Service and the National Institutes of Health Library have signed an agreement that will give NIH scientists enterprise-wide access to SciFinder, a database of chemical substances and related science information, CAS said this week.

According to CAS, a division of the American Chemical Society, the agreement will give scientists access to one of the largest curated collections of publicly disclosed information on chemistry and related research.

It will provide data on chemical substances, reactions, and other related content from more than 10,000 major scientific journals worldwide, patents from 63 global patent authorities, dissertations, meeting abstracts, electronic-only journals and other web sources, CAS said.

Scientists can use the chemical structures, property values, researcher and organization names, and research topics provided in the resource to explore scientific work disclosed by researchers around the world.

The financial details of the arrangement were not disclosed.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.